Q2 2024 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Boosted by William Blair

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) – Investment analysts at William Blair lifted their Q2 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.42). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Fusion Pharmaceuticals’ current full-year earnings is ($1.46) per share. William Blair also issued estimates for Fusion Pharmaceuticals’ Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.65) EPS.

FUSN has been the topic of a number of other research reports. Jonestrading reiterated a “hold” rating on shares of Fusion Pharmaceuticals in a research note on Wednesday, March 20th. Royal Bank of Canada restated a “sector perform” rating and set a $21.00 price target (up previously from $16.00) on shares of Fusion Pharmaceuticals in a research note on Wednesday, March 20th. Jefferies Financial Group restated a “hold” rating and set a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Raymond James restated a “market perform” rating on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Finally, Truist Financial restated a “hold” rating and set a $21.00 price target (up previously from $11.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Thirteen equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.25.

Fusion Pharmaceuticals Stock Performance

FUSN stock opened at $21.40 on Thursday. The company has a quick ratio of 15.01, a current ratio of 15.01 and a debt-to-equity ratio of 0.16. The business’s fifty day simple moving average is $18.27 and its two-hundred day simple moving average is $11.40. Fusion Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $21.58. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -14.56 and a beta of -0.69.

Fusion Pharmaceuticals (NASDAQ:FUSN) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC acquired a new stake in Fusion Pharmaceuticals in the first quarter worth about $376,000. Swiss National Bank acquired a new stake in Fusion Pharmaceuticals in the first quarter worth about $1,827,000. Privium Fund Management B.V. boosted its holdings in Fusion Pharmaceuticals by 77.2% in the first quarter. Privium Fund Management B.V. now owns 251,158 shares of the company’s stock worth $5,355,000 after acquiring an additional 109,408 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Fusion Pharmaceuticals by 66.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 13,920 shares of the company’s stock worth $297,000 after acquiring an additional 5,544 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Fusion Pharmaceuticals in the fourth quarter worth about $7,154,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.